ストックスクリーナーアプリを入手
67.60
0.82%
-0.56
アフターアワーズ：
67.60
前日終値:
$68.16
開ける：
$68.46
24時間の取引高:
1.40M
Relative Volume:
0.78
時価総額：
$3.59B
収益：
-
当期純損益:
$-38.99M
株価収益率:
-22.56
EPS:
-2.9966
ネットキャッシュフロー:
$-24.94M
1週間 パフォーマンス:
+18.91%
1か月 パフォーマンス:
-0.10%
6か月 パフォーマンス:
-5.39%
1年 パフォーマンス:
+33.89%
1日の値動き範囲:
$65.97
$68.46
1週間の範囲:
$61.00
$68.46
52週間の値動き範囲:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
67.60 | 3.62B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-23 | 開始されました | TD Cowen | Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
How to escape a deep drawdown in Soleno Therapeutics Inc.Weekly Market Report & AI Powered Buy and Sell Recommendations - newser.com
Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123 - Insider Monkey
What Wall Street predicts for Soleno Therapeutics Inc. stock priceRecession Risk & AI Forecast Swing Trade Picks - newser.com
Can Soleno Therapeutics Inc. stock deliver sustainable ROEEarnings Summary Report & Capital Efficient Trading Techniques - newser.com
Detecting support and resistance levels for Soleno Therapeutics Inc.2025 Trading Volume Trends & Daily Growth Stock Tips - newser.com
How Soleno Therapeutics Inc. (6XC) stock stacks up against competitors2025 Market Outlook & Smart Money Movement Tracker - newser.com
Is Soleno Therapeutics Inc. stock supported by strong cash flows2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
How Soleno Therapeutics Inc. stock performs in rate cut cycles2025 Support & Resistance & Momentum Based Trading Signals - newser.com
Momentum divergence signals in Soleno Therapeutics Inc. chartMarket Activity Recap & Safe Entry Trade Reports - newser.com
Will Soleno Therapeutics Inc. (6XC) stock justify high valuationOptions Play & Step-by-Step Trade Execution Guides - newser.com
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring an 82.77% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.SLNO - WV News
Soleno Therapeutics Insiders Sold US$23m Of Shares Suggesting Hesitancy - 富途牛牛
SLNO Investor News: If You Have Suffered Losses in Soleno - GlobeNewswire
What analysts say about Soleno Therapeutics Inc stockTrading Volume Surges & Explore Stocks for Free with Our Research Portal - Early Times
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Baird reiterates Outperform rating on Soleno Therapeutics stock after rival’s trial failure - Investing.com Canada
Baird reiterates Outperform rating on Soleno Therapeutics stock after rival’s trial failure By Investing.com - Investing.com South Africa
SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire Inc.
Wells Fargo Sticks to Their Buy Rating for Soleno Therapeutics (SLNO) - The Globe and Mail
Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial - MSN
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):